CFC
LXRX icon

Coyle Financial Counsel’s Lexicon Pharmaceuticals LXRX Stock Holding History

Coyle Financial Counsel’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,500
Closed -$30K – 77
2024
Q2 		$30K Hold
12,500
– – 0.01% 69
2024
Q1 		$30K Buy
+12,500
New +$26.9K 0.01% 69

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Coyle Financial Counsel's LXRX Position: Q3 2024 in Review

Coyle Financial Counsel sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2024, closing a stake of 12,500 shares — an estimated $30K sold.

Coyle Financial Counsel first reported a position in LXRX in Q1 2024 and held it in 2 quarters. The position peaked at $30K in Q2 2024. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

  • Coyle Financial Counsel reported no remaining Lexicon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Coyle Financial Counsel sold 12,500 Lexicon Pharmaceuticals shares in Q3 2024, an estimated $30K.
  • Coyle Financial Counsel first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Coyle Financial Counsel's Lexicon Pharmaceuticals position peaked at $30K in Q2 2024.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on Coyle Financial Counsel's 13F filing for Q3 2024, filed 12 Nov 2024.